LONDON — The drug maker and medical devices company Mallinckrodt Pharmaceuticals said on Monday that it had agreed to buy Therakos from the American private equity firm the Gores Group for about $1.33 billion.
The deal for Therakos, a maker of immunotherapy drugs, is expected to broaden Mallinckrodt’s branded specialty drug segment and to expand its business in hospitals.
21:52 Netflix nears 94 million subscribers 10 years after streaming launch16
18:21 Mark Zuckerberg takes the stand in $2 billion lawsuit claiming Oculus theft8
16:16 Luxottica, Essilor $24 billion merger creates eyewear giant18
19:08 U.S. indicts three Takata executives, fines company $1 billion in faulty air bag scandal16